Neoadjuvant Tislelizumab With Oxaliplatin and Capecitabine in Microsatellite Stable, Locally Advanced Colon Cancer (NETSAC): A Prospective, Single-arm, Single-center, Exploratory Phase II Clinical Study
Latest Information Update: 04 Mar 2025
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- 14 Nov 2023 New trial record
- 09 Nov 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2023 to 13 Nov 2023.